Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is a prospective multi-center randomized control clinical trial which is sponsored
by the researchers. The purpose of this study is to determine the effectiveness of adjuvant
endocrine therapy for operable ER-beta positive, ER-alpha/PR negative, Her-2 negative breast
cancer(triple negative breast cancer, TNBC) patients. The ER-beta positive TNBC patients who
had undergone modified radical mastectomy or breast-conserving surgery were randomly (1:1)
enrolled to receive toremifene (60 mg per day for premenopausal and perimenopausal patients)
/anastrozole(1mg per day for postmenopausal patients) or observation within 4 weeks after
adjuvant chemotherapy and/or radiation therapy if necessary.The follow-up time will be at
least five years. The disease free survival(DFS) and overall survival(OS) between endocrine
group and observation group will be compared to evaluate the effectiveness.